MARSEILLE, France, May 16, 2016 (GLOBE NEWSWIRE) — Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, will today hold an Investor & Analyst Update in New York, USA, from 12:00 to 3:00 pm ET (6:00 to 9:00 pm CET) at NY Palace Hotel, 455 Madison Ave, Spellman Room (5th Floor).
During the meeting, Hervé Brailly, Chief Executive Officer of Innate Pharma, will provide a corporate strategy update including the Company’s approaches towards becoming an integrated biopharmaceutical company.
Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, will discuss Innate’s ongoing development programs, science and R&D strategy in immuno-oncology including:
- An update on the underlying science and preclinical data supporting the development of the Company’s first-in-class checkpoint antibodies targeting NK receptors;
- A description of a new NKp46 bispecific antibody platform;
- The Company’s approach to using novel antibodies for targeting the tumor microenvironment
For live webcast and replay, please go to: http://lifesci.rampard.com/20160516/reg.jsp
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body’s own immune cells to recognize and kill cancer cells.
The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
|
ISIN code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
| Innate Pharma | Press Contacts |
|
Laure-Hélène Mercier Director, Investor Relations |
ATCG Press (France) Marie Puvieux |
| Tel.: +33 (0)4 30 30 30 87 | Mob: +33 (0)6 10 54 36 72 |
| investors@innate-pharma.com | presse@atcg-partners.com |
| Consilium Strategic Communications (ROW) | |
|
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Hendrik Thys |
|
| Tel.: +44 (0)20 3709 5700 | |
| InnatePharma@consilium-comms.com |
Investor & Analyst Update, New York, May 16th, 2016 http://hugin.info/155662/R/2012952/745864.pdf
HUG#2012952
